Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost 0.004% PQ · 1 trial · 3 indications
IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.
| Arm | Type | Description |
|---|---|---|
| Travoprost | EXPERIMENTAL | Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months |
| Timolol | ACTIVE_COMPARATOR | Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months |
| Name | Type | Description |
|---|---|---|
| Travoprost 0.004% PQ ophthalmic solution | DRUG | - |
| Timolol, 0.5% or 0.25% ophthalmic solution | DRUG | Patients 2 months to \< 3 years of age received 0.25% |
| Travoprost Vehicle | DRUG | Inactive ingredients used to maintain masking |
Inclusion Criteria: * Diagnosis of pediatric glaucoma or ocular hypertension. * Qualifying mean IOP at the Eligibility Visit in at least one eye. * Written informed consent, including assent when applicable, MUST be obtained from the parent or legally authorized representative prior to any procedur...
Travoprost 0.004% PQ is an investigational small molecule being studied for the treatment of pediatric glaucoma, specifically to lower elevated intraocular pressure (IOP) in pediatric patients. It is a prostaglandin analog ophthalmic solution developed by Alcon Inc. (NYSE: ALC) and is currently in Phase 3 clinical development.
Travoprost 0.004% PQ is a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. It is being evaluated for its ability to lower elevated IOP in pediatric patients with glaucoma or ocular hypertension.
Travoprost 0.004% PQ is being developed by Alcon Inc., a pharmaceutical company specializing in eye care. Alcon is publicly traded on the New York Stock Exchange under the ticker symbol ALC.
Travoprost 0.004% PQ is in Phase 3 clinical development for pediatric glaucoma. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 3 trial has been completed, with results not yet reported.
Travoprost 0.004% PQ has been studied in one completed Phase 3 trial, NCT01652664, which compared it to timolol (0.5% or 0.25%) in pediatric glaucoma patients. The trial enrolled 184 participants aged 2 months and older and was double-blind and active-controlled.
Travoprost 0.004% PQ is a specific formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. The 'PQ' designation indicates a preservative-free formulation, which may be used to avoid preservative-related side effects. It is being studied specifically for pediatric glaucoma.